title: Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.
abstract: OBJECTIVE
  Mathematical modeling of hepatitis C virus (HCV) kinetics indicated that cellular immune responses contribute to interferon (IFN)-induced clearance of HCV. We investigated a potential role of natural killer (NK) cells in this process.
  
  
  METHODS
  Phenotype and function of blood and liver NK cells were studied during the first 12 weeks of treatment with pegylated IFN-alfa and ribavirin, the time period used to define the early virological response.
  
  
  RESULTS
  Within hours of treatment initiation, NK cells of patients that had an early virological response increased expression of activating receptors NKG2D, NKp30, and CD16 and decreased expression of NKG2C and 2B4, along with inhibitory receptors SIGLEC7 and NKG2A, resulting in NK cell activation. NK cell cytotoxicity, measured by degranulation and tumor necrosis factor-related apoptosis-inducing ligand production, peaked after 24 hours (P<.01), concomitant with an increase in alanine aminotransferase levels (P<.05), whereas IFN-γ production decreased within 6 hours and did not recover for more than 4 weeks (P<.05). NK cells from liver biopsies taken 6 hours after treatment initiation had increased numbers of cytotoxic CD16+NK cells (P<.05) and a trend toward increased production of tumor necrosis factor-related apoptosis-inducing ligand. Degranulation of peripheral blood NK cells correlated with treatment-induced, first-phase decreases in viral load (P<.05) and remained higher in early virological responders than in nonresponders for weeks.
  
  
  CONCLUSIONS
  IFN activates NK cells early after treatment is initiated. Their cytotoxic function, in particular, is strongly induced, which correlates to virologic response. Therefore, NK cell activation indicates responsiveness to IFN-α-based treatment and suggests the involvement of the innate immune cells in viral clearance.
authors: Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA.
authors: Golo
authors: G
authors: Ahlenstiel
authors: Birgit
authors: B
authors: Edlich
authors: Leah J
authors: LJ
authors: Hogdal
authors: Yaron
authors: Y
authors: Rotman
authors: Mazen
authors: M
authors: Noureddin
authors: Jordan J
authors: JJ
authors: Feld
authors: Lauren E
authors: LE
authors: Holz
authors: Rachel H
authors: RH
authors: Titerence
authors: T Jake
authors: TJ
authors: Liang
authors: Barbara
authors: B
authors: Rehermann
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D015550:Cell Degranulation / Q000187:drug effects; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000378:metabolism; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D037102:Lectins / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D008297:Male; D008396:Maryland; D008875:Middle Aged; D055654:NK Cell Lectin-Like Receptor Subfamily C / Q000378:metabolism; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D015214:Antigens, Differentiation, Myelomonocytic; D000998:Antiviral Agents; D016207:Cytokines; D016898:Interferon-alpha; C527054:KLRC1 protein, human; D037102:Lectins; D055654:NK Cell Lectin-Like Receptor Subfamily C; D012367:RNA, Viral; D011994:Recombinant Proteins; C402206:SIGLEC7 protein, human; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D011092:Polyethylene Glycols; D012254:Ribavirin; D007371:Interferon-gamma; D000410:Alanine Transaminase; C100416:peginterferon alfa-2a